Evidence map›Paper›PMID 39803560›Full record

ArticlebioRxiv : the preprint server for biology2024

Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.

Santiago Ramón-García, Rubén González Del Río, María Pilar Arenaz-Callao, Helena Boshoff, Joaquín Rullás, Sara Anca, Mónica Cacho Izquierdo, Esther Porras de Francisco, Esther Pérez Herrán, Angel Santos-Villarejo and 5 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Santiago Ramón-GarcíaDepartment of Microbiology, Radiology, Pediatrics and Public Health, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.ORCID 0000-0002-8480-0325
Rubén González Del RíoGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
María Pilar Arenaz-CallaoResearch & Development Agency of Aragón (ARAID) Foundation, Zaragoza, Spain.
Helena BoshoffTuberculosis Research Section, NIH, Bethesda, USA.
Joaquín RullásGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Sara AncaGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Mónica Cacho IzquierdoGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Esther Porras de FranciscoGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Esther Pérez HerránGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Angel Santos-VillarejoDiscovery DMPK, GSK, Tres Cantos, Madrid, Spain.
Alfonso Mendoza-LosanaGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Santiago Ferrer-BazagaGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Charles J ThompsonDepartment of Microbiology & Immunology, Life Sciences Centre, University of British Columbia, Vancouver, B.C., Canada.
David Barros AguirreGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
Robert H BatesGlobal Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tuberculosis (TB) is historically the world's deadliest infectious disease. New TB drugs that can avoid pre-existing resistance are desperately needed. The β-lactams are the oldest and most widely used class of antibiotics to treat bacterial infections but, for a variety of reasons, they were largely ignored until recently as a potential treatment option for TB. Recently, a growing body of evidence indicates that later-generation carbapenems in the presence of β-lactamase inhibitors could play a role in TB treatment. However, most of these drugs can only be administered intravenously in the clinic. We performed a screening of β-lactams against intracellular

Indexed as

intracellularrepurposingsanfetrinemtuberculosisβ-lactams

Identifiers

PMID39803560
PMCPMC11722294

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.